IP : Tissue Regenix Group plc - DermaPure manufacturing at CellRight Facility

Leeds, 24 April 2018 - Tissue Regenix Group (AIM:TRX) ('Tissue Regenix' or 'The Group') the regenerative medical devices company is pleased to announce that, following the successful completion of the manufacturing technical transfer, it has commenced sales of DermaPure products processed at the CellRight Technologies ('CellRight') facility in San Antonio, Texas.

The completion of the transfer of DermaPure, ahead of schedule, brings a number of benefits to the Group including:

• Expand manufacturing capabilities to meet increasing demands from Global sales and distribution partners
• Improves supply chain production efficiency, and product life cycle management
• Process enhancements increase DermaPure's shelf life from two to three years
• Inhouse manufacturing will facilitate the augmentation of its product portfolio

Commercialised under the recently rebranded TRX BioSurgery division, DermaPure, is being utilised in an increased number of clinical applications including acute and chronic wound care, orthopaedic trauma, dental, and following the exclusive distribution agreement with ARMS medical, urogynaecology and urology.

Steve Couldwell, CEO, Tissue Regenix Group commented: 'We are extremely encouraged by the continued progress integrating CellRight into the Tissue Regenix Group. Completing the transfer of DermaPure manufacturing to our CellRight facility was achieved, ahead of schedule, and incorporated significant process improvements which is a testament to the CellRight team. This is an important strategic milestone in the Group's long-term commercial strategy and I am pleased that the operational synergies are developing as expected. As a result we now have greater flexibility to explore new product opportunities to meet patient demand, expanding the markets we operate in with a reduced manufacturing risk profile.'

For more Information: